Can kidney parenchyma metabolites serve as prognostic biomarkers for long-term kidney function after nephrectomy for renal cell carcinoma? A preliminary study

Barak Rosenzweig¹,²,³, Pedro Recabal¹,⁴, Caroline Gluck⁵, Jonathan A. Coleman¹, Katalin Susztak⁵, A. Ari Hakimi¹,⁶, Edgar A. Jaimes⁷ and Robert H. Weiss⁸

¹Department of Surgery, Urology Services, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, ²Department of Urology, The Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, Affiliated to Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ³The Dr. Pinchas Borenstein Talpiot Medical Leadership Program 2013, The Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, ⁴Urology Service, Fundacion Arturo Lopez Perez, Santiago, Chile, ⁵Department of Medicine, Renal Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia, PA, USA, ⁶Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, ⁷Renal Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA and ⁸Department of Internal Medicine, Division of Nephrology, University of California, Davis, CA, USA

Correspondence to: Barak Rosenzweig; E-mail: barak22@gmail.com

ABSTRACT

Objective. Nephrectomy, the standard of care for localized renal cell carcinoma (RCC), may lead to kidney function loss. Our goal was to identify prognostic biomarkers of postoperative renal function using metabolomics.

Methods. Metabolomics data from benign kidney parenchyma were collected prospectively from 138 patients with RCC who underwent nephrectomy at a single institution. The primary endpoint was the difference between the postoperative and preoperative estimated glomerular filtration (eGFR) rate divided by the elapsed time (eGFR slope). eGFR slope was calculated 2 years post-nephrectomy (GFR1), and at last follow-up (GFR2). A multivariate regularized regression model identified clinical characteristics and abundance of metabolites in baseline benign kidney parenchyma that were significantly associated with eGFR slope. Findings were validated by associating gene expression data with eGFR slope in an independent cohort (n = 58).

Results. Data were compiled on 78 patients (median age 62.6 years, 65.4% males). The mean follow-up was 25 ± 3.4 months for GFR1 and 69.5 ± 23.5 months for GFR2 and 17 (22%) and 32 (41%) patients showed eGFR recovery, respectively.
INTRODUCTION

Surgical resection is considered the standard of care for localized renal cell carcinoma, either in the form of partial or radical nephrectomy (RN) [1]. However, nephrectomy involves the reduction of kidney mass and often leads to the loss of kidney function. This may increase cardiovascular risk, and may result in the need for renal replacement therapy, in reduced quality of life, and in premature death [1]. Moreover, patients undergoing nephrectomy tend to be older, and many suffer from significant medical comorbidities including diabetes mellitus (DM), hypertension (HTN), hyperlipidemia and chronic kidney disease (CKD), which may have an adverse impact on kidney function independently or synergistically with surgery, although several studies have shown that kidney function may recover at longer post-operative follow-up [1–3].

Metabolomics refers to the systematic analysis of all metabolites (molecules involved in metabolism, such as sugars, amino acids, lipids, etc.) in biological specimens. The kidney serves as a pivotal organ in the production, conversion and clearance of metabolites, as well as in the hormonal regulation of systemic metabolism, thus accounting for the intensive study of metabolomics in renal disease [4]. Indeed, several studies have shown associations between relevant metabolites and CKD [5], acute kidney injury [6], diabetic nephropathy [7] and kidney cancer [8], among other kidney pathologies. Histologic analysis of benign kidney parenchyma, which is found adjacent to tumor, at the time of nephrectomy can provide prognostic information for long-term kidney function [9]. Therefore, we hypothesized that a metabolomics molecular analysis of tumor-adjacent benign kidney parenchyma, adding functional data to pathologic description, might unveil metabolites that may be associated with long-term renal function and hence serve as tissue-based prognostic biomarkers for kidney function following nephrectomy. We accordingly designed a hypothesis-generating study with the goal of defining kidney tissue metabolomics that could be used to enhance post-nephrectomy kidney function prediction in addition to the patient’s clinical characteristics and comorbidities.

MATERIALS AND METHODS

This research was approved by Memorial Sloan Kettering (MSK) Cancer Center Institutional Review Board and all patients from which data were collected provided written informed consent. These data were previously described elsewhere [8]. Briefly, for kidney metabolomics, samples of benign kidney parenchyma, as identified by the MSK pathologist, were prospectively collected from 138 specimens of partial or radical nephrectomies performed at MSK Cancer Center (New York). The samples were fresh frozen in liquid nitrogen immediately after their surgical removal and transferred to a −80°C storage at the MSK Translational Kidney Research Program. At a later time point, these samples were sent to Metabolon Inc. (Durham, NC, USA) for abundance quantification, by means of a nontargeted metabolomics gas and liquid chromatography coupled to mass spectrometry approach [8], of 877 metabolites.

Abundances of metabolites were median normalized, and those which fell below the limit of detection per each sample were removed. Subsequently, any metabolite which below the limit-of-detection removal eliminated >75% of its samples was further eliminated, eventually leaving a total of 736 of the 877 metabolites.

The patients were followed-up in the MSK Surgical Clinic as per standard of care. Medical records were retrospectively reviewed, and patient and disease-associated characteristics, such as comorbidities, tumor pathological and clinical stages and nuclear grade (collectively referred to as covariates) were recorded (Table 1). Surgical specimens of the nephrectomies were reviewed by two expert genitourinary pathologists.

Kidney function was calculated as the estimated glomerular filtration rate (eGFR) by means of the CKD Epidemiology Collaboration formula. The intermediate follow-up time point was defined as the follow-up time point closest to 24 months and at least 15 months following surgery (hereby termed GFR1). The long-term follow-up time point was defined as the latest follow-up time point and additionally requiring it to be at least one additional year after the intermediate follow-up time point (hereby termed GFR2).

For patients that underwent a second surgical intervention during follow-up that caused additional renal insult with immediate renal function deterioration, eGFR at GFR2 was evaluated as the last available follow-up prior to that intervention. No patients received a renal transplant or dialysis during the study period.

For each patient, its corresponding eGFR slope at GFR1 was calculated as its eGFR at GFR1 minus its preoperative eGFR and divided by the elapsed time (i.e. GFR1 minus the timepoint at operation). eGFR slope at GFR2 was similarly calculated as the difference between eGFR at GFR2 and preoperative eGFR divided by the difference between its GFR2 and operation time point. Thus, eGFR slopes are a proxy measurement of kidney function outcome, and a positive slope represents an improved eGFR.

A subgroup analysis was performed using the dichotomous variables of age (>70 years versus ≤70 years), nephrectomy type (radical versus partial) and preoperative eGFR (eGFR ≥ 60 mL/min/1.73 m² versus eGFR < 60 mL/min/1.73 m²).

Our aim was to identify benign tissue metabolite abundances and/or patient and disease covariates which are significantly associated with variations of intermediate (GFR1) and long-term eGFR (GFR2) findings and, therefore, could serve as potential prognostic biomarkers. Since the number of

Conclusions. Nephrectomy type, gender, blood lipids and benign parenchyma metabolites at nephrectomy were associated with long-term kidney function. On further study, these metabolites may be useful as potential biomarkers and to identify novel therapeutic targets for malignancy-associated renal disease.

Keywords: chronic kidney disease, fatty acid oxidation, kidney function, metabolomics, nephrectomy, renal cell carcinoma.
Table 1. Clinical characteristics of the entire cohort

| Characteristics | n (%) |
|-----------------|-------|
| Age (mean ± SD), years | 62.6 ± 11.3 |
| Gender | |
| Male | 51 (65.4) |
| Female | 27 (34.6) |
| Race | |
| Caucasian | 68 (87.2) |
| Afro-American | 5 (6.4) |
| Other | 5 (6.4) |
| Preop GFR (mean ± SD), mL/min per 1.73 m² | 67 ± 15 |
| Hypertension (HTN) | 53 (67.9) |
| Diabetes | 12 (15.4) |
| Coronary artery disease | 11 (14.1) |
| Hyperlipidemia | 37 (47.4) |
| Smoking | 38 (48.7) |
| Pack-years (mean ± SD) | 9.1 ± 13.5 |
| BMI (mean ± SD), (kg/m²) | 31.6 ± 5.9 |
| Tumor (T) stage | |
| pT1a | 17 (21.8) |
| pT1b | 9 (11.5) |
| pT2a | 4 (5.1) |
| pT3a | 14 (17.9) |
| pT3b | 33 (42.3) |
| pT4 | 1 (1.3) |
| Fuhrman nuclear grade | |
| G2 | 35 (44.9) |
| G3 | 38 (48.7) |
| G4 | 5 (6.4) |
| Lymph nodes (N) stage | |
| N0 | 41 (52.6) |
| N+ | 37 (47.4) |
| Distant metastasis (M) stage | |
| MO | 76 (97.4) |
| M1 | 2 (2.6) |
| AJCC stage | |
| 1 | 26 (33.3) |
| 2 | 4 (5.1) |
| 3 | 47 (60.3) |
| 4 | 1 (1.3) |
| Nephrectomy type | |
| Radical | 37 (47.4) |
| Partial | 41 (52.6) |
| EBL (mean ± SD), cc | 408 ± 359 |

Preop GFR: preoperative estimated GFR; BMI: body mass index; AJCC: American Joint Committee of Cancer (nodes and metastasis stage were included in the AJCC stage analysis); EBL: estimated blood loss.

Independent variables in our data is much higher than the number of samples, a standard linear model would be inadequate to account for the nonlinearities in this high dimensionality setting. Therefore, we used a multi-response Gaussian family Least Absolute Shrinkage and Selection Operator (LASSO) regularized regression model in order to detect strong associations between the eGFR slopes at both time points and the clinical covariates (Table 1) and metabolite abundances. We treated the eGFR slopes as the response matrix and the covariates and metabolite abundances as factors, including all 736 metabolites and all covariates described in Table 1 (see below). Prior to fitting the LASSO model, we sought to remove all outliers, both in the response as well as in the metabolite abundances and covariates, due to their high potential to drive spurious associations. To this end, the distribution of the responses, the abundances of each metabolite and of the covariates, were each searched for significant outliers using the Grubbs’ test for outliers [10]. We then fitted the LASSO model (employing the R statistical language package glmnet using the mgcv family response), applying a leave-one-out cross-validation strategy and optimizing the regularization parameter lambda (Supplementary data, Figure S1). From this optimal lambda value, we obtained effect estimates of the factors selected by the LASSO model. The glmnet algorithm uses a cyclical coordinate descent, which successively optimizes the objective function over each parameter with others fixed, and cycles repeatedly until convergence. As a result, this package identifies a list of only relevant factors. Unlike a standard linear model, LASSO does not obtain a P-value as a measure of statistical significance of an effect size. Hence, as such, we report the multiple-hypothesis corrected P-value [11] obtained by using a univariable linear model associating eGFR slope with each individual metabolite and covariate selected by the LASSO model.

A separate cohort of subjects with gene expression data from tumor-adjacent benign kidney parenchyma and eGFR slopes was used for confirmation of the metabolomics results. These samples were collected during surgical radical/partial nephrectomy (PN) at the Albert Einstein College of Medicine/Montefiore Medical Center between 2007 and 2011, as described by Gluck et al. [12]. Clinical data were available for these subjects at the time of sample collection as well as before and after nephrectomy. To use these data for confirmation of the metabolomics data analysis, we used the Biochemical Genetic andGenomic (BiGG) database [13] to identify genes involved in the reactions of metabolites we found to be significantly associated with eGFR slope (Supplementary data, Table S1). We additionally required that expression levels of these genes have a significant association with an adjusted eGFR slope in their cohort (Figure 2 and Supplementary data, Figure S2). In other words, intersecting metabolites whose abundances were found to be significantly associated with eGFR slope in one cohort with genes involved in the pathways that generate these metabolites, and which expression levels were found to be significantly associated with eGFR slope in another cohort.

Estimation of eGFR slopes for the validation cohort was determined by linear regression across all available eGFR measurements. As described by Gluck et al. [12], subjects were excluded if their unadjusted eGFR slopes were < -40 mL/min/1.73 m²/year or > 40 mL/min/1.73 m²/year. We used a best linear unbiased predictor to determine the adjusted eGFR slope and the variance of the slope. Using the adjusted eGFR slope as the response, we applied LASSO to all available clinical and histological variables that were associated with eGFR slope on univariate analysis (P < 0.05). It emerged that DM, age and baseline eGFR were the variables that best explained adjusted eGFR slopes. These three variables were then used in a weighted linear regression model for adjusted eGFR slopes which was weighted by inverse variance of the slope. The gene expression level was then individually added to this baseline model to identify genes whose expression level improved the model fit [akaike information criterion (AIC) < 176] and were significantly associated with outcome of adjusted eGFR slopes (P < 0.05).

Data availability
The data underlying this article will be shared on reasonable request to the corresponding author.
RESULTS

Out of the 138 patients with available metabolomics data, 6 patients were excluded due to intra-operative complications and 51 patients did not meet the inclusion criteria for both intermediate and long-term eGFR follow-up data (GFR1 and GFR2). Three additional patients were defined as outliers (see Materials and Methods section). Our final cohort included 78 patients characterized as described in Table 1. The mean intermediate follow-up (GFR1) was 25 ± 3 months, and the mean long-term follow-up (GFR2) was 69.5 ± 23.5 months. The mean preoperative eGFR was 67 ± 15 mL/min/1.73 m², and the mean eGFR slopes for GFR1 and GFR2 were −0.17 ± 0.28 and −0.04 ± 0.22, respectively. Seventeen (22%) patients had improved eGFR at GFR1, and 32 (41%) had improved eGFR at GFR2 (i.e. positive eGFR slope). Significant associations between eGFR slopes and nephrectomy type, hyperlipidemia, and gender were identified by the LASSO model for both GFR1 and GFR2 (Figure 1).

Overall, 23 metabolites were found to have a significant association with eGFR slopes, and 18 of them are identified (Supplementary data, Table S2). Three identified and two unidentified metabolites that were significantly associated with both eGFR slopes (GFR1 and GFR2) were identified by the analysis of the entire cohort (Table 2 and Supplementary data, Table S2).

In the subgroup analysis, we investigated the relevance of a preoperative eGFR (>60 mL/min/1.73 m² cutoff, n = 51, versus <60 mL/min/1.73 m², n = 27), age (>70 years, n = 21 versus ≤70 years, n = 57) and nephrectomy type (radical, n = 37 versus partial, n = 41). Nephrectomy type, blood lipids and gender were significantly associated with eGFR slope regardless of preoperative kidney function. The same three clinical covariates were significantly associated with eGFR slope in patients who were ≤70 years. No clinical covariates or metabolites were significantly associated with eGFR slope in patients undergoing PN, while blood lipids and gender had significant associations with eGFR slope in patients undergoing RN (Supplementary data, Table S3). Metabolites associated with eGFR slopes in the subgroup analyses are shown in Tables 3, 4 and Supplementary data, Table S3.

To attempt to validate our metabolomics data, we evaluated a second cohort of 58 patients from another institution from which we had obtained genomic data (Supplementary data, Figure S2a). The mean follow-up for this confirmation cohort was 2.4 ± 1.5 years. The mean age of the subjects at the time of nephrectomy was 65.5 ± 11.1 years. Fifty percent of the subjects had confirmed DM and 78% of subjects had confirmed HTN. The mean baseline estimated eGFR was 65.8 ± 26.5 mL/min/1.73 m². Of the original cohort, nine of the metabolites associated with eGFR slope had genes that were identified as being involved in their chemical reactions according to the BiGG database [13] (Supplementary data, Table S1). In our confirmation cohort, two of these genes were significantly associated with adjusted eGFR slope (P < 0.05) and improved model fit (AIC < 176). Both genes related to the same metabolite, 1-arachidonoylglycero-phosphoethanolamine. Addition of lecithin-cholesterol acyltransferase (LCAT) gene expression to the model lowered the AIC of the model to 166, and it was negatively associated with adjusted eGFR slope (β = −0.767, P = 0.0011) (Figure 2). Addition of phospholipase A2 group III gene expression to the model lowered the AIC of the model to 173, and it was negatively associated with adjusted eGFR slope (β = −0.525, P = 0.03) (Supplementary data, Figure S2).

DISCUSSION

It is well recognized that renal function is often affected after either partial or RN, yet other than using the criteria of CKD at diagnosis, it is not known which patients may or may not recover renal function post-operatively. Recent reports from our institution had shown that kidney function may indeed recover following nephrectomy [2, 3]. Histological analysis of non-neoplastic renal parenchyma at time of nephrectomy and severity of glomerulosclerosis was found to be associated with renal function deterioration and increased cardiovascular risk, suggesting that this analysis could be used as a personalized post-nephrectomy follow-up tool [9]. In this study, we evaluated the association of clinical covariates and abundances of metabolites in benign kidney parenchyma with eGFR slope in order to
Phenylalanylmethionine Peptide Dipeptide – a product of phosphatidylethanolamine hydrolysis mediated by [13] (Figure 2). 1-Arachidonoylglycerophosphoethanolamine is also metabolized to cholesterol ester, facilitated by the activity of the LCAT enzyme and metabolized to cholesterol ester, facilitated by the activity of the LCAT enzyme. 1-Arachidonoylglycerophosphoethanolamine, which is an FAO metabolite, 1-arachidonoylglycerophosphoethanolamine, which is a product of cholesterol c + phosphatidylethanolamine metabolized to cholesterol ester+ 1-arachidonoylglycerophosphoethanolamine, facilitated by the activity of the LCAT enzyme [13] (Figure 2). 1-Arachidonoylglycerophosphoethanolamine is also a product of phosphatidylethanolamine hydrolysis mediated by phospholipase A2 1-arachidonoylglycerophosphoethanolamine [13]. Both of these findings were further validated by an independent cohort, significantly associating these enzymes’ genes expression levels with eGFR slope (Figure 2 and Supplementary data, Figure S2).

Interestingly, the LCAT enzyme had been described as part of the lipid metabolism, specifically, high-density lipoprotein [20]. Lack of the LCAT enzyme is characterized by the association of dyslipidemia, corneal opacities, anemia and progressive nephropathy and kidney transplantation was described in a patient carrying this homozygosity [21]. Our current validation cohort associated higher LCAT expression levels with negative eGFR slope (Figure 2 and Supplementary data, Figure S2).

Despite the extensive knowledge regarding lipid abnormalities in patients with end-stage renal disease, clinical evidence supporting an association between cholesterol levels and the development of renal dysfunction is relatively limited in humans, although it has been reported and is well-supported by animal models [16–18]. In earlier studies looking at the role of fatty acid oxidation (FAO) in CKD pathogenesis, a lower expression of key enzymes and regulators of FAO, as well as an increased intracellular lipid deposition were demonstrated in tubulointerstitial fibrosis [19]. Our current analysis associated kidney function recovery with an FAO metabolite, 1-arachidonoylglycerophosphoethanolamine, which is the product of cholesterol c + phosphatidylethanolamine metabolized to cholesterol ester+ 1-arachidonoylglycerophosphoethanolamine, facilitated by the activity of the LCAT enzyme [13] (Figure 2). 1-Arachidonoylglycerophosphoethanolamine is also a product of phosphatidylethanolamine hydrolysis mediated by phospholipase A2 1-arachidonoylglycerophosphoethanolamine [13]. Both of these findings were further validated by an independent cohort, significantly associating these enzymes’ genes expression levels with eGFR slope (Figure 2 and Supplementary data, Figure S2).

Interestingly, the LCAT enzyme had been described as part of the lipid metabolism, specifically, high-density lipoprotein [20]. Lack of the LCAT enzyme is characterized by the association of dyslipidemia, corneal opacities, anemia and progressive nephropathy and kidney transplantation was described in a patient carrying this homozygosity [21]. Our current validation cohort associated higher LCAT expression levels with negative eGFR slope (Figure 2 and Supplementary data, Figure S2).

Despite the extensive knowledge regarding lipid abnormalities in patients with end-stage renal disease, clinical evidence supporting an association between cholesterol levels and the development of renal dysfunction is relatively limited in humans, although it has been reported and is well-supported by animal models [16–18]. In earlier studies looking at the role of fatty acid oxidation (FAO) in CKD pathogenesis, a lower expression of key enzymes and regulators of FAO, as well as an increased intracellular lipid deposition were demonstrated in tubulointerstitial fibrosis [19]. Our current analysis associated kidney function recovery with an FAO metabolite, 1-arachidonoylglycerophosphoethanolamine, which is the product of cholesterol c + phosphatidylethanolamine metabolized to cholesterol ester+ 1-arachidonoylglycerophosphoethanolamine, facilitated by the activity of the LCAT enzyme [13] (Figure 2). 1-Arachidonoylglycerophosphoethanolamine is also a product of phosphatidylethanolamine hydrolysis mediated by phospholipase A2 1-arachidonoylglycerophosphoethanolamine [13]. Both of these findings were further validated by an independent cohort, significantly associating these enzymes’ genes expression levels with eGFR slope (Figure 2 and Supplementary data, Figure S2).

Interestingly, the LCAT enzyme had been described as part of the lipid metabolism, specifically, high-density lipoprotein [20]. Lack of the LCAT enzyme is characterized by the association of dyslipidemia, corneal opacities, anemia and progressive nephropathy and kidney transplantation was described in a patient carrying this homozygosity [21]. Our current validation cohort associated higher LCAT expression levels with negative eGFR slope (Figure 2 and Supplementary data, Figure S2).

Despite the apparently counter-intuitive finding (i.e. higher rather than lower), biological reactions often show comparable mechanisms (e.g.HMG) CoA reductase under statin treatment), and may suggest compensation for a malfunctioning enzyme. Our finding that the expression of phospholipase A2, another enzyme related to a reaction creating this metabolite, correlated with eGFR slope further supports the importance of these reactions in post-nephrectomy kidney function recovery.

Given that renal function tends to decrease with aging, there is some controversy over the benefits of curative surgical treatment for renal masses versus conservative treatments and renal function preservation as populations grow older [22], thus increasing the importance of risk stratification of surgical...

### Table 2. Abundances of all metabolites in benign kidney parenchyma significantly associated with eGFR slopes and their effect size (GFR1 data presented)

| Biochemical name | Super pathway | Sub-pathway | Effect size | q-value |
|------------------|---------------|-------------|-------------|---------|
| 1-Arachidonoylglycerophosphoethanolamine | Lipid | Lysolipid | 0.01589 | 0.01682 |
| Leucyserylserine | Peptide | Dipeptide | −0.00319 | 0.08498 |
| Stachydrine | Xenobiotics | Food component/plant | −0.03130 | 0.00014 |
| X-11315 | NA | NA | −0.08447 | 0.00059 |
| X-15691 | NA | NA | −0.04079 | 0.01251 |

Negative and positive effect size, respectively, indicate that kidney function (eGFR slope) is negatively and positively associated with the abundance of that metabolite (i.e. a possible biomarkers of deterioration and recovery, respectively). X-11315 – unnamed metabolite number 11315 (LC/MS positive, Retention Time Index = 1210, Mass = 130.2, data adopted from Metabolon Inc.); X-15691 – unnamed metabolite number 15691; (LC/MS negative, Retention Time Index = 5170, Mass = 387.2, data adopted from Metabolon Inc.); NA, not available.

### Table 3. Subgroup analysis by age for abundances of metabolites in benign kidney parenchyma significantly associated with eGFR slopes and their effect size

| Biochemical name | Super pathway | Sub-pathway | >70 years | <70 years |
|------------------|---------------|-------------|-----------|-----------|
|                  |               |             | Effect size | q-value |
| Pentadecanoate (15:0) | Lipid | Long chain fatty acid | 0.22627 | 0.00306 |
| Glycerophosphorylcholine | Lipid | Glycerolipid metabolism | 0.02065 | 0.08561 |
| 2-Hydroxypalmitate | Lipid | Fatty acid monohydroxy | −0.13646 | 0.00306 |
| Glycerol | Lipid | Glycerolipid metabolism | −0.01032 | 0.00349 |
| Uracil | Nucleotide | Pyrimidine metabolism uracil containing | −0.00929 | 0.01412 |
| p-cresol sulfate | Amino acid | Phenylalanine and tyrosine metabolism | −0.02526 | 0.00306 |
| Pyroglutamine | Amino acid | Glutamate metabolism | −0.00340 | 0.02842 |
| N-acetyl-aspartyl-glutamate | Amino acid | Glutamate metabolism | − | 0.00059 |
| Nicotinamide ribonucleotide | Cofactors and vitamins | Nicotinate and nicotinamide metabolism | − | 0.00101 |
| Phenylalaninmethionine | Peptide | Dipeptide | − | 0.00630 |

>70 – subgroup analysis for patients >70 years old; <70 – subgroup analysis for patients 70 years old or younger. Negative and positive effect size indicate that kidney function (eGFR slope) is negatively and positively associated with the abundance of that metabolite, respectively (i.e. possible biomarkers of deterioration and recovery, respectively). GFR1 data are presented. Four unnamed metabolites are not shown.
candidates among elderly patients. Our cohort included 21 (26.9%) patients >70 years of age, and 10 metabolites were associated with eGFR slope among them (Table 3). Two of these 10 metabolites were positively associated with eGFR slope: one of them is glycerophosphocholine, a renal medullary organic osmolyte that protects renal medullary cells from the high interstitial concentrations of NaCl and urea [23]. Glycerol and p-cresol sulfate were negatively associated metabolites. The effect of glycerol on renal function has been applied in animal models for renal failure induction [24], while p-cresol sulfate has been reported as a uremic toxin associated with CKD stage, CKD progression and mortality in CKD patients, as well as with the phenomenon of compensatory renal growth [25, 26].

Interestingly, several of the metabolites found to be associated with eGFR slope in older patients have also been associated with old age in different pathologies. For example, metabolites related to gut bacterial metabolism (e.g. p-cresol sulfate), which are altered in response to peroxisome proliferator-activated receptor-alpha activation and take part in FAO (e.g. 2-hydroxypalmitate), have been associated with physical function in functionally limited older adults [27].

Although many urologists support PN over RN based on perceived benefits, such as improvement in all-cause mortality and eGFR preservation, studies on such benefits have shown conflicting results [28]. Furthermore, the benefits of PN have been argued to be limited to certain patient subgroups [29]. Our analysis isolated some metabolites which may provide prognostic information and, as such, aid in risk stratification of these patients. Our analysis of the RN subgroup found gender and blood lipids to correlate with eGFR slope. Metabolites associated with eGFR slope in that subgroup fully coincided with the results for the entire cohort (Supplementary data, Table S3), as noted above. Not surprisingly, neither clinical covariates nor metabolomics correlated with eGFR slope in patients undergoing PN, which can be explained by contralateral kidney compensation and the smaller changes in eGFR slope following nephron-sparing surgery.

Abundances of several metabolites that have been previously associated with CKD were also identified in the present work as predictors of a negative eGFR slope, e.g. stachydrine (Table 2) [30]. Zabor et al. correlated various covariates with kidney function recovery following nephrectomy in patients with a preoperative eGFR of <60 mL/min/1.73 m² [2]. Moreover, a confirmatory study validated preoperative eGFR as a predictor of kidney function recovery [3]. This subgroup was also represented in this study, and three metabolites (p-cresol sulfate, pyroglutamine and phenylacetylglutamine, Table 4) showed a negative association with eGFR slope in patients with a preoperative eGFR of <60 mL/min/1.73 m². As noted earlier, p-cresol sulfate has been associated with both CKD and compensatory renal growth [25, 26, 31], while phenylacetylglutamine, another gut-derived uremic toxin, has been associated with cardiovascular disease and mortality in CKD patients [32]. The abundances of five metabolites were associated with eGFR slope in patients with a preoperative eGFR ≥ 60 mL/min/1.73 m², among which is octanoyl carnitine, that had been reported in plasma and urine of CKD patients [33]. Despite this resemblance to already reported CKD metabolite profiles, the identification of the signature of new metabolites in the setting of post-nephrectomy eGFR slope described in this study may support...
an alternative pathophysiology for CKD versus post-
nephrectomy renal function, as has been suggested before [34].

Incorporation of metabolomics as renal function prognostic
tools can be used to guide a patient-tailored post-nephrectomy
follow-up protocol. Renal mass biopsy, recommended by some,
can possibly elaborate such application to the pre-surgical
setting [35].

Limitations of this study include the possible effect of cancer
on its metabolic surroundings. While such effect has been pre-
viously suggested, conflicting evidence exists regarding actual
alteration of benign parenchyma metabolomics adjacent to
cancer [36]. Furthermore, even if some alterations do exist, the
fact that we correlated tissue metabolomics with final clinical
outcomes (i.e. kidney function), the relevance of such might not
be of the essence to the suggested hypothesis. Also, the small
size of our cohort relative to the number of comorbidities and
the abundances of the tested metabolites renders the study un-
derpowered to detect small but nevertheless significant effects.

In addition, due to the limited size of our data, we did not test
for associations between eGFR slopes and any type of interac-
tions between the comorbidities and metabolite abundances.
From a clinical perspective, possible sources of bias include the
retrospective nature of this study. Only 86 out of 138 samples
had eGFR data available at both time points. Long-term kidney
function is a major factor in preoperative decision-making, and
while GFR1 may represent long-term surgical insult following
confirming the importance of a single chemical process by
identifying two genes to correspond with a single metabolite
emphasizes its strong effect rather than the lack of importance
for the rest of the metabolites identified by the primary
analysis.

To the best of our knowledge, this study is the first to report
an association between abundances of metabolites in benign
kidney parenchyma at the time of nephrectomy and postopera-
tive kidney function. This finding serves as proof of concept for
chemical processes taking place at that time to be associated
with long-term kidney function. We believe that identifying the
significance of several metabolites and further specifying and
confirming the importance of a single chemical process by the
correlation between 1-arachidonoylglycerophosphoethanol-
amine and LCAT enzyme should support future endeavors in
the search for kidney tissue prognostic biomarkers and poten-
tial therapeutic targets.

**CONCLUSION**

Nephrectomy type, gender and blood lipids, as well as benign
parenchyma metabolites at the time of nephrectomy are associ-
ated with long-term kidney function. A subgroup analysis
further identified unique metabolite patterns according to older
age, type of nephrectomy and preoperative eGFR. These data
propose that metabolites can serve as potential future bio-
markers and that related metabolic reactions can serve as pos-
ible therapeutic targets.

**SUPPLEMENTARY DATA**

Supplementary data are available at ckj online.

**ACKNOWLEDGEMENTS**

We thank our patients for donating their tissue and the
team members of the MSK TKCRP for the advancement of
kidney cancer research. The first author would like to deeply
thank his childhood friend, Nimrod Rubinstein, whose
professional skills are responsible for the heavy-lifting part of this work.

**FUNDING**

This research was supported by the CKD Biomarkers Consortium Pilot and Feasibility Studies Program, The BioCon Scientific Data Coordinating Center, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK: U01 DK103225) and NIH Center Grant P30 CA008748.

**CONFLICT OF INTEREST STATEMENT**

Dr E.A.J. reports other financial activities outside the submitted work as Chief Medical Officer and Stockholder at Goldilocks Therapeutics, Inc. All other authors declare no COI.

**REFERENCES**

1. Malcolm JB, Bagrodia A, Derweesh IH et al. Comparison of rates and risk factors for developing chronic renal insufficiency, proteinuria and metabolic acidosis after radical or partial nephrectomy. BJU Int 2009; 104: 476–481
2. Zabor EC, Furberg H, Mashni J et al. Factors associated with recovery of renal function following radical nephrectomy for kidney neoplasms. Clin J Am Soc Nephrol 2016; 11: 101–107
3. Zabor EC, Furberg H, Lee B et al. Long-term renal function recovery following radical nephrectomy for kidney cancer: results from a multicenter confirmatory study. J Urol 2018; 199: 921–926
4. Weiss RH, Kim K. Metabolomics in the study of kidney diseases. Nat Rev Nephrol 2012; 8: 22–33
5. Sekula P, Goek ON, Quaye L et al. A metabolome-wide association study of kidney function and disease in the general population. J Am Soc Nephrol 2015; 27: 1175–1188
6. Portilla D, Li S, Nagothu KK et al. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int 2006; 69: 2194–2204
7. Niewczas MA, Sirich TL, Mathew AV et al. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int 2014; 85: 1214–1224
8. Hakimi AA, Reznik E, Lee CH et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 2016; 29: 104–116
9. Sejima T, Honda M, Takenaka A. Renal parenchymal histopathology predicts life-threatening chronic kidney disease as a result of radical nephrectomy. Int J Urol 2015; 22: 14–21
10. Grubbs FE. Sample criteria for testing outlying observations. Ann Math Statist 1950; 21: 27–50
11. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995; 57: 289–300
12. Gluck C, Qiu C, Han SY et al. Kidney cytosine methylation changes improve renal function decline estimation in patients with diabetic kidney disease. Nat Commun 2019; 10: 2461
13. King ZA, Lu J, Dräger A et al. BiGG models: a platform for integrating, standardizing and sharing genome-scale models. Nucleic Acids Res 2016; 44: D515–D522
14. Huang WC, Levey AS, Serio AM et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006; 7: 735–740
15. Mulroney SE, Woda C, Johnson M, Pesce C. Gender differences in renal growth and function after uninephrectomy in adult rats. Kidney Int 1999; 56: 944–953
16. Samuelsson O, Attman PO, Knight-Gibson C et al. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol 1998; 9: 1482–1488
17. Schaeffner ES, Kurth T, Curhan GC et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084–2091
18. Kasiske BL, O’Donnell MP, Schmitz PG et al. Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990; 37: 880–891
19. Kang HM, Ahn SH, Choi P et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med 2015; 21: 37–46
20. Kunnen S, Van Eck M. Lecithin: cholesterol acyltransferase: old friend or foe in atherosclerosis? J Lipid Res 2012; 53: 1783–1799
21. Ahmad SB, Miller M, Hanish S et al. Sequential kidney-liver transplantation from the same living donor for lecithin cholesterol acyl transferase deficiency. Clin Transplant 2016; 30: 1370–1374
22. Lane BR, Abouassaly R, Gao T et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 2010; 116: 3119–3126
23. Gallazzini M, Burg MB. What’s new about osmotic regulation of glycerophosphocholine. Physiology (Bethesda) 2009; 24: 245–249
24. Westenfelder C, Arevaloj C, Crawford PW et al. Renal tubular function in glycerol-induced acute renal failure. Kidney Int 1980; 18: 432–444
25. Lin CJ, Wu V, Wu PC et al. Meta-analysis of the associations of p-cresyl sulfate (PCS) and indoxyl sulfate (IS) with cardiovascular events and all-cause mortality in patients with chronic renal failure. PLoS One 2015; 10: e0132589
26. Rosenzweig B, Rubinstein ND, Reznik E et al. Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients. PLoS One 2017; 12: e0180350
27. Lustgarten MS, Price LL, Chalé A et al. Metabolites related to gut bacterial metabolism, peroxisome proliferator-activated receptor-alpha activation, and insulin sensitivity are associated with physical function in functionally-limited older adults. Aging Cell 2014; 13: 918–925
28. Kunath F, Schmidt S, Krabbe LM et al. Partial nephrectomy versus radical nephrectomy for clinical localised renal masses. Cochrane Database Syst Rev 2017; 5: CD012045
29. Smaldone MC, Egleston B, Uzzo RG et al. Does partial nephrectomy result in a durable overall survival benefit in the medicare population? J Urol 2012; 188: 2089–2094
30. Yu B, Zheng Y, Nettleton JA et al. Serum metabolomic profiling and incident CKD among African Americans. Clin J Am Soc Nephrol 2009; 4: 1410–1417
31. Huang ST, Shu KH, Cheng CH et al. Serum total p-cresol and indoxyl sulfate correlated with stage of chronic kidney disease in renal transplant recipients. Transplant Proc 2012; 44: 621–624
32. Poens R, Claes K, Evenepoel P et al. Microbiota-derived phenylacetylglutamine associates with overall mortality and cardiovascular disease in patients with CKD. J Am Soc Nephrol 2016; 27: 3479–3487
33. Chen DQ, Cao G, Chen H et al. Gene and protein expressions and metabolomics exhibit activated redox signaling and
wnt/β-catenin pathway are associated with metabolite dys-
function in patients with chronic kidney disease. Redox Biol
2017; 12: 505–521
34. Demirjian S, Lane BR, Derweesh IH et al. Chronic kidney dis-
ease due to surgical removal of nephrons: relative rates of
progression and survival. J Urol 2014; 192: 1057–1063
35. Patel RM, Parkhomenko E, Kaler KS et al. Renal mass bi-
opsy: an oncological conundrum. Curr Opin Urol 2018; 28:
360–363
36. Wettersten HI, Aboud OA, Lara PN et al. Metabolic reprog-
gramming in clear cell renal cell carcinoma. Nat Rev Nephrol
2017; 13: 410–419